INAB Stock Rating Reiterated, $6 Target Set on Trial Data
Published on · Source: investing.com
AI Summary
Summarized by AI from the source belowH.C. Wainwright has reiterated their rating on IN8bio (INAB) with a price target of $6, citing data from ongoing trials. This target indicates a potential upside based on the outcomes of the trial, which investors are closely monitoring. The reiteration of the rating suggests confidence in the company's performance and potential market position. These developments may impact investor sentiment and trading volumes as the trial progresses.
Informational only, not financial advice. Content is AI-generated and may contain errors. How this works.
Get the weekly market brief
One email every Monday: what moved, why, and what to watch. Free, unsubscribe anytime.
Get stories like this as they break
Our Telegram channel posts every market story the moment it is published. Free, and you can mute or leave anytime.
